摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-cyclobutylthiourea | 572889-33-9

中文名称
——
中文别名
——
英文名称
1-cyclobutylthiourea
英文别名
N-cyclobutylthiourea;Cyclobutylthiourea
1-cyclobutylthiourea化学式
CAS
572889-33-9
化学式
C5H10N2S
mdl
——
分子量
130.214
InChiKey
KTNJMTPGENILGB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    8
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.8
  • 拓扑面积:
    70.1
  • 氢给体数:
    2
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    1-cyclobutylthiourea(R)-N-(tert-butoxycarbonyl)-2-(2-chloroacetyl)pyrrolidineN,N-二甲基甲酰胺 为溶剂, 生成 tert-butyl (R)-2-(2-(cyclobutylamino)thiazol-4-yl)pyrrolidine-1-carboxylate
    参考文献:
    名称:
    2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors
    摘要:
    TNF-alpha converting enzyme (TACE) inhibitors are promising agents to treat inflammatory disorders and cancer. We have investigated novel tartrate diamide TACE inhibitors where the tartrate core binds to zinc in a unique tridentate fashion. Incorporating (R)-2-(2-N-alkylaminothiazol-4-yl)pyrrolidines into the left hand side amide of the tartrate scaffold led to the discovery of potent and selective TACE inhibitors, some of which exhibited good rat oral bioavailability. (C) 2011 Published by Elsevier Ltd.
    DOI:
    10.1016/j.bmcl.2011.01.002
  • 作为产物:
    描述:
    环丁基胺potassium thioacyanate盐酸 作用下, 以 四氢呋喃1,4-二氧六环 为溶剂, 反应 17.0h, 以100%的产率得到1-cyclobutylthiourea
    参考文献:
    名称:
    [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS
    [FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
    摘要:
    本发明提供噻唑和氧唑化合物,含有这些化合物的组合物,以及用作药用剂的制备方法和使用方法。
    公开号:
    WO2009032667A1
点击查看最新优质反应信息

文献信息

  • Thiazole And Oxazole Kinase Inhibitors
    申请人:Adjabeng George
    公开号:US20110190280A1
    公开(公告)日:2011-08-04
    The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    本发明提供噻唑和氧唑化合物,含有这些化合物的组合物,以及制备这些化合物的方法和将其用作药物的方法。
  • Utilization of a nitrogen–sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors
    作者:Shuqun Lin、Stephen T. Wrobleski、John Hynes、Sidney Pitt、Rosemary Zhang、Yi Fan、Arthur M. Doweyko、Kevin F. Kish、John S. Sack、Mary F. Malley、Susan E. Kiefer、John A. Newitt、Murray McKinnon、James Trzaskos、Joel C. Barrish、John H. Dodd、Gary L. Schieven、Katerina Leftheris
    DOI:10.1016/j.bmcl.2010.07.102
    日期:2010.10
    The design, synthesis, and structure-activity relationships (SAR) of a series of 2-aminothiazol-5-yl-pyrimidines as novel p38α MAP kinase inhibitors are described. These efforts led to the identification of 41 as a potent p38α inhibitor that utilizes a unique nitrogen-sulfur intramolecular nonbonding interaction to stabilize the conformation required for binding to the p38α active site. X-ray crystallographic studies that confirm the proposed binding mode of this class of inhibitors in p38 α and provide evidence for the proposed intramolecular nitrogen-sulfur interaction are discussed.
  • Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents
    作者:Marvin J. Meyers、Micky D. Tortorella、Jing Xu、Limei Qin、Zhengxiang He、Xingfen Lang、Wentian Zeng、Wanwan Xu、Li Qin、Michael J. Prinsen、Francis M. Sverdrup、Christopher S. Eickhoff、David W. Griggs、Jonathan Oliva、Peter G. Ruminski、E. Jon Jacobsen、Mary A. Campbell、David C. Wood、Daniel E. Goldberg、Xiaorong Liu、Yongzhi Lu、Xin Lu、Zhengchao Tu、Xiaoyun Lu、Ke Ding、Xiaoping Chen
    DOI:10.1021/ml400412x
    日期:2014.1.9
    Given the threat of drug resistance, there is an acute need for new classes of antimalarial agents that act via a unique mechanism of action relative to currently used drugs. We have identified a set of druglike compounds within the Tres Cantos Anti-Malarial Set (TCAMS) which likely act via inhibition of a Plasmodium aspartic protease. Structure-activity relationship analysis and optimization of these aminohydantoins demonstrate that these compounds are potent nanomolar inhibitors of the Plasmodium aspartic proteases PM-II and PM-IV and likely one or more other Plasmodium aspartic proteases. Incorporation of a bulky group, such as a cyclohexyl group, on the aminohydantion N-3 position gives enhanced antimalarial potency while reducing inhibition of human aspartic proteases such as BACE. We have identified compound 8p (CWHM-117) as a promising lead for optimization as an antimalarial drug with a low molecular weight, modest lipophilicity, oral bioavailability, and in vivo antimalarial activity in mice.
  • [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
    申请人:SMITHKLINE BEECHAM CORP
    公开号:WO2009032667A1
    公开(公告)日:2009-03-12
    The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    本发明提供噻唑和氧唑化合物,含有这些化合物的组合物,以及用作药用剂的制备方法和使用方法。
  • 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors
    作者:Chaoyang Dai、Dansu Li、Janeta Popovici-Muller、Lianyun Zhao、Vinay M. Girijavallabhan、Kristin E. Rosner、Brian J. Lavey、Razia Rizvi、Bandarpalle B. Shankar、Michael K.C. Wong、Zhuyan Guo、Peter Orth、Corey O. Strickland、Jing Sun、Xiaoda Niu、Shiying Chen、Joseph A. Kozlowski、Daniel J. Lundell、John J. Piwinski、Neng-Yang Shih、M. Arshad Siddiqui
    DOI:10.1016/j.bmcl.2011.01.002
    日期:2011.5
    TNF-alpha converting enzyme (TACE) inhibitors are promising agents to treat inflammatory disorders and cancer. We have investigated novel tartrate diamide TACE inhibitors where the tartrate core binds to zinc in a unique tridentate fashion. Incorporating (R)-2-(2-N-alkylaminothiazol-4-yl)pyrrolidines into the left hand side amide of the tartrate scaffold led to the discovery of potent and selective TACE inhibitors, some of which exhibited good rat oral bioavailability. (C) 2011 Published by Elsevier Ltd.
查看更多